BCL2 Inhibition: A New Paradigm for the Treatment of AML and Beyond
- Author(s)
- Wei, AH; Roberts, AW;
- Details
- Publication Year 2023-06,Volume 7,Issue #6,Page e912
- Journal Title
- HemaSphere
- Publication Type
- Review
- Abstract
- Altering the natural history of acute myeloid leukemia (AML) in unfit and older patients has proved a highly challenging hurdle, despite several decades of concerted clinical trial effort. The arrival of venetoclax (VEN) to the clinical stage represents the most important therapeutic advance to date for older patients with AML. In this review, we will explain how and why VEN works, summarize its remarkable pathway to regulatory approval, and highlight the key milestones that have been important for its successful development in AML. We also provide perspectives on some of the challenges associated with using VEN in the clinic, emerging knowledge regarding mechanisms of treatment failure, and current clinical research directions likely to shape how this drug and others in this new class of anticancer agents are used in the future.
- Publisher
- Lippincott Williams & Wilkins
- Department(s)
- Clinical Haematology
- PubMed ID
- 37304937
- Publisher's Version
- https://doi.org/10.1097/HS9.0000000000000912
- Open Access at Publisher's Site
https://doi.org/10.1097/hs9.0000000000000912- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-09-12 01:58:48
Last Modified: 2023-09-12 01:59:21